Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease

NCT ID: NCT00003913

Last Updated: 2010-04-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 390 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1998-12-31
• Study Completion Date: 2005-08-31

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.

PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood transplantation plus combination chemotherapy in treating patients who have hematologic cancer or nonmalignant hematologic disease.

Detailed Description

OBJECTIVES:

• Determine the efficacy of umbilical cord blood transplantation, as measured by durable neutrophil engraftment, in patients with malignant or nonmalignant hematological disease.
• Determine the disease-free survival and long-term survival in patients treated with this regimen.
• Determine the incidence of neutrophil engraftment, primary and secondary graft failure, platelet engraftment, and RBC engraftment in patients treated with this regimen.
• Determine the incidence and severity of acute and chronic graft-versus-host disease, complications (infection, veno-occlusive disease, interstitial pneumonitis), relapse, other malignancies, lymphoproliferative disorders, and posttransplantation myelodysplasia in patients treated with this regimen.
• Determine the immune reconstitution in patients treated with this regimen.

OUTLINE: This is a multicenter study. Patients are stratified according to disease group (malignant vs nonmalignant). Patients with malignant disease are further stratified according to quality of HLA match (1 or 2/6 vs 3/6 vs 4/6 vs 5/6 or 6/6), cell dose, and age.

Patients are assigned to one of three conditioning regimens, depending on disease.

• Group A (malignant disease ): Patients undergo total body irradiation (TBI) once on day -8 and twice daily on days -7 to -4. Male patients with acute lymphocytic leukemia (ALL) undergo radiotherapy boost to testes. Patients receive cyclophosphamide (CTX) IV on days -3 and -2 and methylprednisolone (MePRDL) IV and anti-thymocyte globulin (ATG) IV on days -3 to -1.
• Group B (inborn errors of metabolism/storage disease): Patients receive oral busulfan (BU) every 6 hours on days -6 and -5, CTX IV on days -4 and -3, and MePRDL IV and ATG IV every 12 hours on days -2 and -1.
• Group C (other nonmalignant diseases): Patients receive oral BU every 6 hours on days -9 to -6, CTX IV on days -5 to -2, and MePRDL IV and ATG IV on days -3 to -1.

Patients in all groups receive cord blood IV over a maximum of 30 minutes on day 0. Patients also receive MePRDL IV with the first half of the infusion administered immediately before the cord blood infusion and filgrastim (G-CSF) IV beginning 4 hours after transplantation and continuing until blood counts recover.

Patients are followed at 30, 60, and 90 days; at 6 months; and then annually thereafter.

PROJECTED ACCRUAL: Approximately 390 patients will be accrued for this study within 5 years.

Conditions

Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases

Study Design

• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

anti-thymocyte globulin

Intervention Type: BIOLOGICAL

filgrastim

Intervention Type: BIOLOGICAL

busulfan

Intervention Type: DRUG

cyclophosphamide

Intervention Type: DRUG

methylprednisolone

Intervention Type: DRUG

umbilical cord blood transplantation

Intervention Type: PROCEDURE

radiation therapy

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• One of the following diagnoses:

• Acute myeloid leukemia (AML), with or without myelodysplastic syndromes

• Not in first complete remission (CR)* with translocations t(8;21) and inv (16) unless failure of first-line induction therapy
• Not in first CR* with translocations t(15;17) abnormality unless:

• Failure of first-line induction therapy OR
• Molecular evidence of persistent disease
• Not in first CR with Down syndrome
• Patients with third or greater medullary relapse or refractory disease (other than primary induction failures) receive busulfan/melphalan conditioning regimen NOTE: * CR defined by no greater than 5% blasts in marrow
• Acute lymphocytic leukemia (ALL)

• Not in first CR OR
• High-risk ALL in first CR, with high risk defined as one of the following:

• Hypoploidy (no greater than 44 chromosomes)
• Pseudodiploidy with translocations or molecular evidence of t(9;22), 11q23, or t(8;14) (except B-cell ALL) with or without MLL gene arrangement
• Elevated WBC at presentation

• Age 6-12 months: greater than 100,000/mm^3
• Age 10-17 years: greater than 200,000/mm^3
• Age 18: greater than 20,000/mm^3
• Failed to achieve CR after 4 weeks of induction therapy
• Patients with B-ALL must not be in first CR, must meet at least one of the high-risk criteria specified above, or must not meet any of the following criteria:

• Translocation t(8;14)
• Blasts have surface immunoglobulins
• CD10 positive
• Patients with third or greater medullary relapse or refractory disease (other than primary induction failures) receive busulfan/melphalan conditioning regimen
• Chronic myelogenous leukemia, meeting criteria for 1 of the following:

• Accelerated phase
• Chronic phase if 1 year from diagnosis without a matched unrelated bone marrow donor AND unresponsive to or unable to tolerate interferon
• Blast crisis, defined as greater than 30% promyelocytes plus blasts in bone marrow

• Patients receive busulfan/melphalan conditioning regimen
• Acute undifferentiated leukemia (AUL), infant leukemia, or biphenotypic leukemia

• Patients with third or greater medullary relapse or refractory disease (other than primary induction failures) receive busulfan/melphalan conditioning regimen
• Juvenile myelomonocytic leukemia meeting the following criteria:

• No Philadelphia chromosome
• Bone marrow blasts less than 30%
• Peripheral blood monocytes greater than 1,000/mm^3
• At least 2 of the following:

• Peripheral blood spontaneous growth and/or sargramostim (GM-CSF) hypersensitivity
• Increased hemoglobin F for age
• Clonal abnormalities (e.g., monosomy 7 or RAS mutations)
• Peripheral blood with myeloid precursors
• WBC greater than 10,000/mm^3
• Myelodysplastic syndromes defined by the following:

• Refractory anemia (RA)
• RA with ringed sideroblasts
• RA with excess blasts (RAEB)
• RAEB in transformation
• Chronic myelomonocytic leukemia
• Paroxysmal nocturnal hemoglobinuria
• Hodgkin's lymphoma or non-Hodgkin's lymphoma beyond first CR or primary induction failures AND chemosensitive (greater than 50% reduction in tumor mass size)
• Inborn error of metabolism including, but not limited to, Hurler's syndrome, adrenoleukodystrophy (ALD), Maroteaux-Lamy syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy, fucosidosis, or mannosidosis

• For ALD patients over age 5, IQ must be at least 80
• For all other patients over age 5, IQ must be at least 70
• For all patients age 5 and under, developmental quotient or clinical neurodevelopmental examination should demonstrate potential for stabilization at a level of functioning where continuous life support (e.g., mechanical ventilation) would not be predicted to be required in the year after transplantation
• Combined immune deficiencies including, but not limited to:

• Severe combined immunodeficiency (SCID) requiring cytoreduction
• Wiskott-Aldrich syndrome
• Leukocyte adhesion defect
• Chediak-Higashi disease
• X-linked lymphoproliferative disease
• Adenosine deaminase deficiency
• Purine nucleoside phosphorylase deficiency
• X-linked SCID
• Common variable immune deficiency
• Nezelof's syndrome
• Cartilage hair hypoplasia
• No dyskeratosis congenita
• No ALL, AML, AUL, or biphenotypic leukemia in third or higher medullary relapse or refractory disease other than primary induction failure
• No primary myelofibrosis or myelofibrosis grade 3 or worse
• No active CNS leukemia involvement (CSF with WBC greater than 5/mm^3 and malignant cells on cytospin)
• No consenting 5/6 or 6/6 HLA-matched related donor available
• 3-6/6 HLA-matched unrelated umbilical cord blood donor available

PATIENT CHARACTERISTICS:

Age:

• See Disease Characteristics
• 18 and under

Performance status:

• Karnofsky 70-100%, if age 16 to 18
• Lansky 50-100%, if under age 16

Life expectancy:

• Not specified

Hematopoietic:

• See Disease Characteristics

Hepatic:

• Bilirubin less than 2.5 mg/dL
• SGOT less than 5 times upper limit of normal

Renal:

• Creatinine normal for age OR
• Creatinine clearance or glomerular filtration rate greater than 50% lower limit of normal for age

Cardiovascular:

• If symptomatic:

• LVEF greater than 40% (or shortening fraction greater than 26%) and improves with exercise OR
• Shortening fraction greater than 26%

Pulmonary:

• If symptomatic:

• DLCO, FEV_1, and FEC greater than 45% predicted OR
• Oxygen saturation greater than 85% on room air

Other:

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No uncontrolled viral, bacterial, or fungal infection

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics
• At least 1 year since prior allogeneic stem cell transplantation (SCT) with cytoreductive preparative therapy
• At least 6 months since prior autologous SCT
• No concurrent thrombopoietic growth factors

Chemotherapy:

• See Disease Characteristics
• See Biologic therapy

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• Not specified

• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

Fred Hutchinson Cancer Center

OTHER

Sponsor Role: lead

Principal Investigators

Colleen Delaney, MD, MSC

Role: STUDY_CHAIR

Fred Hutchinson Cancer Center

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, United States

Children's Hospital Los Angeles

Los Angeles, California, United States

Jonsson Comprehensive Cancer Center, UCLA

Los Angeles, California, United States

Children's Hospital of Orange County

Orange, California, United States

Children's National Medical Center

Washington D.C., District of Columbia, United States

Indiana University Cancer Center

Indianapolis, Indiana, United States

Children's Hospital of New Orleans

New Orleans, Louisiana, United States

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support

Bethesda, Maryland, United States

Warren Grant Magnuson Clinical Center

Bethesda, Maryland, United States

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Boston, Massachusetts, United States

Spectrum Health and DeVos Children's Hospital

Grand Rapids, Michigan, United States

University of Minnesota Cancer Center

Minneapolis, Minnesota, United States

Children's Mercy Hospital

Kansas City, Missouri, United States

Cardinal Glennon Children's Hospital

St Louis, Missouri, United States

Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, United States

North Shore University Hospital

Manhasset, New York, United States

James P. Wilmot Cancer Center at University of Rochester Medical Center

Rochester, New York, United States

Duke Comprehensive Cancer Center

Durham, North Carolina, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Ireland Cancer Center

Cleveland, Ohio, United States

Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, United States

Medical City Dallas Hospital

Dallas, Texas, United States

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Countries

United States

Other Identifiers

FHCRC-1330.00

Identifier Type: -

Identifier Source: secondary_id

UMN-MT-9817

Identifier Type: -

Identifier Source: secondary_id

NCI-G99-1523

Identifier Type: -

Identifier Source: secondary_id

CDR0000067092

Identifier Type: REGISTRY

Identifier Source: secondary_id

1330.00

Identifier Type: -

Identifier Source: org_study_id

NCT00053755

Identifier Type: -

Identifier Source: nct_alias